Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kyle Null, Varun Kumar, Trevor Lissoos & Michelle Luo. (2018) Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. Journal of Medical Economics 21:11, pages 1102-1109.
Read now
Read now
Marc Berns & Daniel W. Hommes. (2016) Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 25:2, pages 129-143.
Read now
Read now
Articles from other publishers (7)
Silvio Danese, Elmer Schabel, Mark Andrew Ainsworth & Laurent Peyrin-Biroulet. (2020) Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut 69:7, pages 1157-1161.
Crossref
Crossref
Johan Burisch, Hillel Vardi, Doron Schwartz, Michael Friger, Gediminas Kiudelis, Juozas Kupčinskas, Mathurin Fumery, Corinne Gower-Rousseau, Laszlo Lakatos, Peter L Lakatos, Renata D'Incà, Alessandro Sartini, Daniela Valpiani, Martina Giannotta, Naila Arebi, Dana Duricova, Martin Bortlik, Stefania Chetcuti Zammit, Pierre Ellul, Natalia Pedersen, Jens Kjeldsen, Jóngerð Maria Miné Midjord, Kári Rubek Nielsen, Karina Winther Andersen, Vibeke Andersen, Konstantinos H Katsanos, Dimitrios K Christodoulou, Viktor Domislovic, Zeljko Krznaric, Shaji Sebastian, Pia Oksanen, Pekka Collin, Luisa Barros, Fernando Magro, Riina Salupere, Hendrika Adriana Linda Kievit, Adrian Goldis, Ioannis P Kaimakliotis, Jens F Dahlerup, Carl Eriksson, Jonas Halfvarson, Alberto Fernandez, Vicent Hernandez, Svetlana Turcan, Elena Belousova, Ebbe Langholz, Pia Munkholm, Selwyn Odes, Niksa Turk, Silvija Cukovic-Cavka, Anastasia Nicolaou, Milan Lukas, Olga Shonová, Birgitte Blichfeldt, Dorte Marker, Katrine Carlsen, Petra Weimers, Clays Aalykke, Karen Kudsk, Ida Vind, Niels Thorsgaard, Alexandros Skamnelos, Dimitrios Politis, Zsuzsanna Vegh, Peterne Demenyi, Szabina Nemethne Kramli, Giualia Dal Piaz, Alessia Santini, Giulia Girardin, Limas Kupcinskas, Laimas Jonaitis, Irena Valantiene, Romanas Zykus, Ruta Kucinskiene, Daniela Lazar, Inna Nikulina, Luisa de Castro, Juan-Ramon Pineda, Santos Pereira, Jesus Martinez-Cadilla, Luciano Sanroman, Montserrat Figueira, David Martinez Ares, Jose-Ignacio Rodriguez-Prada, Amalia Carmona, Carlos Gonzalez-Portela, Ulla-Britt Widen, Sally Myers, Katherine Ashton & Emma Whitehead. (2020) Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology & Hepatology 5:5, pages 454-464.
Crossref
Crossref
BO Ajayi, IA Adedara & EO Farombi. (2018) Protective mechanisms of 6-gingerol in dextran sulfate sodium-induced chronic ulcerative colitis in mice. Human & Experimental Toxicology 37:10, pages 1054-1068.
Crossref
Crossref
Orly Sarid, Vered Slonim-Nevo, Doron Schwartz, Michael Friger, Ruslan Sergienko, Avihu Pereg, Hillel Vardi, Elena Chernin, Terri Singer, Dan Greenberg & Shmuel Odes. (2018) Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn’s Disease. International Journal of Behavioral Medicine 25:3, pages 341-350.
Crossref
Crossref
Nadia Pillai, Mark Dusheiko, Bernard Burnand & Valérie Pittet. (2017) A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLOS ONE 12:10, pages e0185500.
Crossref
Crossref
Shmuel Odes. (2016) Refractory Ulcerative Proctitis—A Brief Review. Open Journal of Gastroenterology 06:10, pages 239-248.
Crossref
Crossref
Dan Greenberg, Doron Schwartz, Hillel Vardi, Michael Friger, Orly Sarid, Vered Slonim-Nevo & Shmuel Odes. (2015) Health-Related Utility Weights in a Cohort of Real-World Crohn’s Disease Patients. Journal of Crohn's and Colitis 9:12, pages 1138-1145.
Crossref
Crossref